The precision medicine company also is accelerating its push into diabetes, depression, and cardiology after getting its solid-tumor test turnaround down to 9 days.
The new Qlucore Diagnostics software builds on the recently updated Qlucore Omics Explorer platform, initially to help clinicians diagnose and treat leukemia.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
